These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 21353720

  • 1. Use of G-CSF during concurrent chemotherapy and thoracic radiotherapy in patients with limited-stage small-cell lung cancer safety data from a phase II trial.
    Sheikh H, Colaco R, Lorigan P, Blackhall F, Califano R, Ashcroft L, Taylor P, Thatcher N, Faivre-Finn C.
    Lung Cancer; 2011 Oct; 74(1):75-9. PubMed ID: 21353720
    [Abstract] [Full Text] [Related]

  • 2. Omitting elective nodal irradiation during thoracic irradiation in limited-stage small cell lung cancer--evidence from a phase II trial.
    Colaco R, Sheikh H, Lorigan P, Blackhall F, Hulse P, Califano R, Ashcroft L, Taylor P, Thatcher N, Faivre-Finn C.
    Lung Cancer; 2012 Apr; 76(1):72-7. PubMed ID: 22014897
    [Abstract] [Full Text] [Related]

  • 3. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: report of Fox Chase Cancer Center study 94-001.
    Langer CJ, Movsas B, Hudes R, Schol J, Keenan E, Kilpatrick D, Yeung C, Curran W.
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-89-S12-95. PubMed ID: 9331129
    [Abstract] [Full Text] [Related]

  • 4. Results of a phase II study of high-dose thoracic radiation therapy with concurrent cisplatin and etoposide in limited-stage small-cell lung cancer (NCCTG 95-20-53).
    Schild SE, Bonner JA, Hillman S, Kozelsky TF, Vigliotti AP, Marks RS, Graham DL, Soori GS, Kugler JW, Tenglin RC, Wender DB, Adjei A.
    J Clin Oncol; 2007 Jul 20; 25(21):3124-9. PubMed ID: 17634491
    [Abstract] [Full Text] [Related]

  • 5. Phase I study of concurrent chemoradiation with pemetrexed and cisplatin followed by consolidation pemetrexed for patients with unresectable stage III non-small cell lung cancer.
    Cardenal F, Arnaiz MD, Morán T, Jové J, Nadal E, Porta R, Solé JM, Brao I, Palmero R, Fuentes R, Núñez I, Caveda E, Cassinello A.
    Lung Cancer; 2011 Oct 20; 74(1):69-74. PubMed ID: 21353323
    [Abstract] [Full Text] [Related]

  • 6. Concurrent cisplatin-etoposide chemotherapy plus thoracic radiotherapy for limited-stage small cell lung cancer. Japanese Lung Cancer Chemotherapy Group in Japanese Clinical Oncology Group.
    Ariyoshi Y, Fukuoka M, Furuse K, Saijo N, Ikegami H, Nishiwaki Y, Tamura T, Shimoyama M, Suemasu K.
    Jpn J Clin Oncol; 1994 Oct 20; 24(5):275-81. PubMed ID: 7967106
    [Abstract] [Full Text] [Related]

  • 7. Use of high-dose etoposide/ifosfamide/carboplatin/epirubicin and peripheral blood progenitor cell transplantation in limited-disease small cell lung cancer.
    Brugger W, Frommhold H, Pressler K, Mertelsmann R, Kanz L.
    Semin Oncol; 1995 Feb 20; 22(1 Suppl 2):3-8. PubMed ID: 7531368
    [Abstract] [Full Text] [Related]

  • 8. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide.
    Turrisi AT, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, Wagner H, Aisner S, Johnson DH.
    N Engl J Med; 1999 Jan 28; 340(4):265-71. PubMed ID: 9920950
    [Abstract] [Full Text] [Related]

  • 9. Cisplatin/etoposide chemotherapy combined with twice daily thoracic radiotherapy for limited small-cell lung cancer: a clinical phase II trial.
    Chen GY, Jiang GL, Wang LJ, Qian H, Fu XL, Yang H, Wu KL, Zhao S.
    Int J Radiat Oncol Biol Phys; 2005 Jan 01; 61(1):70-5. PubMed ID: 15629596
    [Abstract] [Full Text] [Related]

  • 10. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.
    Faivre-Finn C, Snee M, Ashcroft L, Appel W, Barlesi F, Bhatnagar A, Bezjak A, Cardenal F, Fournel P, Harden S, Le Pechoux C, McMenemin R, Mohammed N, O'Brien M, Pantarotto J, Surmont V, Van Meerbeeck JP, Woll PJ, Lorigan P, Blackhall F, CONVERT Study Team.
    Lancet Oncol; 2017 Aug 01; 18(8):1116-1125. PubMed ID: 28642008
    [Abstract] [Full Text] [Related]

  • 11. Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer.
    Schild SE, Bonner JA, Shanahan TG, Brooks BJ, Marks RS, Geyer SM, Hillman SL, Farr GH, Tazelaar HD, Krook JE, Geoffroy FJ, Salim M, Arusell RM, Mailliard JA, Schaefer PL, Jett JR.
    Int J Radiat Oncol Biol Phys; 2004 Jul 15; 59(4):943-51. PubMed ID: 15234027
    [Abstract] [Full Text] [Related]

  • 12. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group.
    Bunn PA, Crowley J, Kelly K, Hazuka MB, Beasley K, Upchurch C, Livingston R, Weiss GR, Hicks WJ, Gandara DR.
    J Clin Oncol; 1995 Jul 15; 13(7):1632-41. PubMed ID: 7602352
    [Abstract] [Full Text] [Related]

  • 13. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group.
    Keller SM, Adak S, Wagner H, Herskovic A, Komaki R, Brooks BJ, Perry MC, Livingston RB, Johnson DH.
    N Engl J Med; 2000 Oct 26; 343(17):1217-22. PubMed ID: 11071672
    [Abstract] [Full Text] [Related]

  • 14. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study.
    Ettinger DS, Berkey BA, Abrams RA, Fontanesi J, Machtay M, Duncan PJ, Curran WJ, Movsas B, Byhardt RW, Radiation Therapy Oncology Group 9609.
    J Clin Oncol; 2005 Aug 01; 23(22):4991-8. PubMed ID: 15939930
    [Abstract] [Full Text] [Related]

  • 15. Phase I study of hypofractionated dose-escalated thoracic radiotherapy for limited-stage small-cell lung cancer.
    Yee D, Halperin R, Hanson J, Nijjar T, Butts C, Smylie M, Reiman T, Roa W.
    Int J Radiat Oncol Biol Phys; 2006 Jun 01; 65(2):466-73. PubMed ID: 16563653
    [Abstract] [Full Text] [Related]

  • 16. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group.
    Segawa Y, Ueoka H, Kiura K, Kamei H, Tabata M, Sakae K, Hiraki Y, Kawahara S, Eguchi K, Hiraki S, Harada M.
    Br J Cancer; 2000 Jan 01; 82(1):104-11. PubMed ID: 10638975
    [Abstract] [Full Text] [Related]

  • 17. Cisplatin and etoposide chemotherapy combined with early concurrent twice-daily thoracic radiotherapy for limited-disease small cell lung cancer in elderly patients.
    Okamoto K, Okamoto I, Takezawa K, Tachibana I, Fukuoka M, Nishimura Y, Nakagawa K.
    Jpn J Clin Oncol; 2010 Jan 01; 40(1):54-9. PubMed ID: 19837690
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Prophylactic granulocyte colony-stimulating factor allows escalation of chemotherapeutic dose intensity in advanced epithelial ovarian cancer.
    Fanning J, Hilgers RD.
    Gynecol Oncol; 1996 Dec 01; 63(3):323-7. PubMed ID: 8946866
    [Abstract] [Full Text] [Related]

  • 20. Phase I study of tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in limited-stage small cell lung cancer (S0004): a Southwest Oncology Group study.
    Le QT, McCoy J, Williamson S, Ryu J, Gaspar LE, Edelman MJ, Dakhil SR, Sides SD, Crowley JJ, Gandara DR, Southwest oncology group.
    Clin Cancer Res; 2004 Aug 15; 10(16):5418-24. PubMed ID: 15328179
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.